Market cap
$58 Mln
Recently Viewed
Clear All$23.93
$2.71
(12.77%)
As on 17-Feb-2023 09:30EDT
Market cap
$58 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.7
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-43 Mln
ROE
-0.4 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0.8
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
43,328,300
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Gemini Therapeutics (GMTX)
| 20.3 | -- | 42.9 | 33.7 | -- | -- | -- |
|
BSE Sensex*
| -9.2 | 4.5 | -6.1 | -2.9 | 8.2 | 9.5 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
|---|---|---|
|
Gemini Therapeutics (GMTX)
| -31.6 | -73.5 |
|
S&P Small-Cap 600
| -17.4 | 25.3 |
|
BSE Sensex
| 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Gemini Therapeutics (GMTX)
|
23.9 | 58.5 | 0.0 | -43.4 | -- | -40.2 | -- | 0.7 |
| 4.9 | 26.5 | 0.1 | -16.7 | -46,093.9 | -71.7 | -- | 0.8 |
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of... the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts. Read more
Interim Pres & CEO and Exec. Chairperson
Dr. Georges Gemayel C.F.A., Ph.D.
Interim Pres & CEO and Exec. Chairperson
Dr. Georges Gemayel C.F.A., Ph.D.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Gemini Therapeutics Inc (GMTX) is $23.93 (NASDAQ) as of 17-Feb-2023 09:30 EDT. Gemini Therapeutics Inc (GMTX) has given a return of 33.69% in the last 1 years.
Since, TTM earnings of Gemini Therapeutics Inc (GMTX) is negative, P/E ratio is not available.
The P/B ratio of Gemini Therapeutics Inc (GMTX) is 0.68 times as on 17-Feb-2023, a 87 discount to its peers’ median range of 5.16 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of Gemini Therapeutics Inc (GMTX) are Rs -- and Rs -- as of 28-Apr-2026.
Gemini Therapeutics Inc (GMTX) has a market capitalisation of $ 58 Mln as on 17-Feb-2023. As per SEBI classification, it is a Small Cap company.
Before investing in Gemini Therapeutics Inc (GMTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.